Emilia Modolo Pinto

List of Publications by Year
in descending order

53	1,566	279487	315357
papers	citations	23 h-index	38 g-index

59	59	59	2053
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical and Functional Significance of TP53 Exon 4â€“Intron 4 Splice Junction Variants. Molecular Cancer Research, 2022, 20, 207-216.	1.5	4
2	Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1159-1169.	1.8	7
3	TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC. Cancers, 2022, 14, 1655.	1.7	3
4	Environmental Contaminants Modulate Breast Cancer Development and Outcome in TP53 p.R337H Carriers and Noncarriers. Cancers, 2022, 14, 3014.	1.7	1
5	The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Research, 2021, 81, 2442-2456.	0.4	9
6	KDM6B Inhibition Has Anti-Tumor Activity in Anaplastic Wilms Tumor Cells Associated with WT1 And MYCN Pathway Silencing. , 2021, , .		0
7	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. Journal of Clinical Oncology, 2021, 39, 2463-2473.	0.8	38
8	Adrenocortical Tumors in Children With Constitutive Chromosome 11p15 Paternal Uniparental Disomy: Implications for Diagnosis and Treatment. Frontiers in Endocrinology, 2021, 12, 756523.	1.5	2
9	An update on the central nervous system manifestations of Liâ€“Fraumeni syndrome. Acta Neuropathologica, 2020, 139, 669-687.	3.9	44
10	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.4	32
11	What 20 years of research has taught us about the TP53 p.R337H mutation. Cancer, 2020, 126, 4678-4686.	2.0	30
12	A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. British Journal of Cancer, 2020, 122, 1231-1241.	2.9	8
13	XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances, 2020, 6, eaba3231.	4.7	37
14	Pediatric adrenocortical tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101448.	2.2	29
15	Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors. Cancers, 2020, 12, 506.	1.7	17
16	Contemporary preclinical human models of adrenocortical carcinoma. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 139-144.	0.6	15
17	From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion. Journal of Physical Education and Sports Management, 2019, 5, a003921.	0.5	4
18	Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. Nature Communications, 2019, 10, 5806.	5.8	27

#	Article	IF	Citations
19	DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. JCO Precision Oncology, 2019, 3, 1-21.	1.5	6
20	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. Acta Neuropathologica, 2018, 136, 315-326.	3.9	26
21	Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Childrenâ€™s Oncology Group Study. Journal of Clinical Oncology, 2017, 35, 3956-3963.	0.8	33
22	Abstract 4889: Characterizing the viromes in pediatric cancers through whole genome sequencing. , 2017, , .		0
23	Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study. Clinical Cancer Research, 2016, 22, 6247-6255.	3.2	22
24	Genomic landscape of paediatric adrenocortical tumours. Nature Communications, 2015, 6, 6302.	5.8	166
25	The E180splice mutation in the GHR gene causing Laron syndrome: Witness of a Sephardic Jewish exodus from the Iberian Peninsula to the New World?. American Journal of Medical Genetics, Part A, 2014, 164, 1204-1208.	0.7	19
26	Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent. Clinical Cancer Research, 2013, 19, 1740-1747.	3.2	29
27	Insulin-like growth factor 1 gene (CA)n repeats and a variable number of tandem repeats of the insulin gene in Brazilian children born small for gestational age. Clinics, 2013, 68, 785-791.	0.6	3
28	An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers. Oncogenesis, 2012, 1, e1-e1.	2.1	3
29	The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Molecular and Cellular Endocrinology, 2012, 351, 37-43.	1.6	103
30	Differential elemental distribution of retained particles along the respiratory tract. Inhalation Toxicology, 2011, 23, 459-467.	0.8	7
31	Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor. Familial Cancer, 2011, 10, 141-146.	0.9	13
32	Possible role of a radiation-induced p53 mutation in a Nelsonâ€™s syndrome patient with a fatal outcome. Pituitary, 2011, 14, 400-404.	1.6	18
33	Children with Cushingâ€™s syndrome: primary pigmented nodular adrenocortical disease should always be suspected. Pituitary, 2011, 14, 61-67.	1.6	5
34	TP53-Associated Pediatric Malignancies. Genes and Cancer, 2011, 2, 485-490.	0.6	30
35	Glucose-dependent insulinotropic peptide receptor overexpression in adrenocortical hyperplasia in MEN1 syndrome without loss of heterozygosity at the 11q13 locus. Clinics, 2011, 66, 529-33.	0.6	6
36	Congenital Hyperinsulinism in Brazilian Neonates: A Study of Histology, KATP Channel Genes, and Proliferation of Î² Cells. Pediatric and Developmental Pathology, 2010, 13, 375-384.	0.5	7

#	Article	IF	Citations
37	iASPP: A Novel Protein Involved in Pituitary Tumorigenesis?. Frontiers of Hormone Research, 2010, 38, 70-76.	1.0	5
38	Familial predisposition to adrenocortical tumors: Clinical and biological features and management strategies. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 477-490.	2.2	30
39	Pathogenesis of Adrenocortical Tumors. , 2010, , 41-52.		0
40	Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary, 2009, 12, 297-303.	1.6	65
41	Molecular analysis of CYP21A2 can optimize the followâ€up of positive results in newborn screening for congenital adrenal hyperplasia. Clinical Genetics, 2009, 76, 503-510.	1.0	30
42	The degree of external genitalia virilization in girls with 21â€hydroxylase deficiency appears to be influenced by the CAG repeats in the androgen receptor gene. Clinical Endocrinology, 2008, 68, 226-232.	1.2	26
43	Cryptic intragenic deletion of the SHOX gene in a family with LÃ©ri-Weill dyschondrosteosis detected by Multiplex Ligation-Dependent Probe Amplification (MLPA). Arquivos Brasileiros De Endocrinologia E Metabologia, 2008, 52, 1382-1387.	1.3	9
44	ABO genotyping in leukemia patients reveals new ABO variant alleles. Genetics and Molecular Research, 2008, 7, 87-94.	0.3	16
45	Evaluating the Roles of Follicle-Stimulating Hormone Receptor Polymorphisms in Gonadal Hyperstimulation Associated with Severe Juvenile Primary Hypothyroidism. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2312-2317.	1.8	46
46	CLASSICAL OSTEOBLASTOMA, ATYPICAL OSTEOBLASTOMA, AND OSTEOSARCOMA. A COMPARATIVE STUDY BASED ON CLINICAL, HISTOLOGICAL, AND BIOLOGICAL PARAMETERS. Clinics, 2007, 62, 167-174.	0.6	50
47	Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: Preferential expression of somatostatin receptor subtype 3. Journal of Endocrinological Investigation, 2006, 29, 826-830.	1.8	42
48	Deletion Mapping of Chromosome 17 in Benign and Malignant Adrenocortical Tumors Associated with the Arg337His Mutation of the p53 Tumor Suppressor Protein. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2976-2981.	1.8	34
49	Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arquivos Brasileiros De Endocrinologia E Metabologia, 2004, 48, 647-650.	1.3	109
50	Maternal isodisomy causing homozygosity for a dominant activating mutation of the luteinizing hormone receptor gene in a boy with familial male-limited precocious puberty. Clinical Endocrinology, 2003, 59, 533-534.	1.2	4
51	Population Genetics of Nine Short Tandem Repeat Loci. American Journal of Forensic Medicine and Pathology, 2002, 23, 186-190.	0.4	6
52	Three Novel Mutations in CYP21 Gene in Brazilian Patients with the Classical Form of 21-Hydroxylase Deficiency Due to a Founder Effect. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4314-4317.	1.8	57
53	An Inherited Mutation Outside the Highly Conserved DNA-Binding Domain of the p53 Tumor Suppressor Protein in Children and Adults with Sporadic Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4970-4973.	1.8	183